Can Fite Biopharma Stock Performance

CANF Stock  USD 4.43  0.04  0.89%   
The firm shows a Beta (market volatility) of -1.79, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Can Fite are expected to decrease by larger amounts. On the other hand, during market turmoil, Can Fite is expected to outperform it. At this point, Can Fite Biopharma has a negative expected return of -0.79%. Please make sure to confirm Can Fite's skewness, and the relationship between the total risk alpha and day median price , to decide if Can Fite Biopharma performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Can Fite Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more

Actual Historical Performance (%)

One Day Return
(0.89)
Five Day Return
4.73
Year To Date Return
0.68
Ten Year Return
(99.93)
All Time Return
(99.97)
Last Split Factor
1:10
Dividend Date
2019-05-10
Last Split Date
2023-01-09
1
Can-Fite BioPharma Shareholders Approve Key Proposals - TipRanks
11/10/2025
2
Is Can Fite BioPharma Ltd. Depositary Receipt stock entering bullish territory - Earnings Beat Target Return Focused Stock Picks - newser.com
11/13/2025
3
Can-Fite BioPharma Ltd. Stock Soars as Patient Achieves 9-Year Cancer-Free Milestone - parameter.io
11/18/2025
4
Will Can Fite BioPharma Ltd. Depositary Receipt stock outperform Dow Jones index - Risk Management Daily Growth Stock Tips - newser.com
11/21/2025
5
Can-Fite Provides Update on Clinical and Financial Status
12/16/2025
6
Is Can Fite BioPharma Ltd. Depositary Receipt stock a top pick in earnings season - 2025 Market Outlook Daily Growth Stock Investment Tips -
12/19/2025
7
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
12/26/2025
8
Can-Fite BioPharma Discloses Resignation of Director Yaacov Goldman - TipRanks
01/16/2026
9
Can-Fite BioPharma Calls March 3 Special Meeting to Address NYSE Audit Committee Non-Compliance - TipRanks
01/27/2026
Begin Period Cash Flow4.3 M
Total Cashflows From Investing Activities1.5 M

Can Fite Relative Risk vs. Return Landscape

If you would invest  845.00  in Can Fite Biopharma on October 31, 2025 and sell it today you would lose (402.00) from holding Can Fite Biopharma or give up 47.57% of portfolio value over 90 days. Can Fite Biopharma is currently does not generate positive expected returns and assumes 7.4047% risk (volatility on return distribution) over the 90 days horizon. In different words, 66% of stocks are less volatile than Can, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Can Fite is expected to under-perform the market. In addition to that, the company is 9.81 times more volatile than its market benchmark. It trades about -0.11 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of volatility.

Can Fite Target Price Odds to finish over Current Price

The tendency of Can Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 4.43 90 days 4.43 
about 82.3
Based on a normal probability distribution, the odds of Can Fite to move above the current price in 90 days from now is about 82.3 (This Can Fite Biopharma probability density function shows the probability of Can Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Can Fite Biopharma has a beta of -1.79 suggesting as returns on its benchmark rise, returns on holding Can Fite Biopharma are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Can Fite is expected to outperform its benchmark. Additionally Can Fite Biopharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Can Fite Price Density   
       Price  

Predictive Modules for Can Fite

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Can Fite Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.234.5711.97
Details
Intrinsic
Valuation
LowRealHigh
0.203.9611.36
Details
Naive
Forecast
LowNextHigh
0.094.4211.82
Details
2 Analysts
Consensus
LowTargetHigh
3.193.503.89
Details

Can Fite Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Can Fite is not an exception. The market had few large corrections towards the Can Fite's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Can Fite Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Can Fite within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.81
β
Beta against Dow Jones-1.79
σ
Overall volatility
1.78
Ir
Information ratio -0.14

Can Fite Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Can Fite for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Can Fite Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Can Fite Biopharma generated a negative expected return over the last 90 days
Can Fite Biopharma has high historical volatility and very poor performance
The company reported the previous year's revenue of 674 K. Net Loss for the year was (7.88 M) with profit before overhead, payroll, taxes, and interest of 560 K.
Can Fite Biopharma currently holds about 12.77 M in cash with (7.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.
Can Fite Biopharma has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: Can-Fite BioPharma Calls March 3 Special Meeting to Address NYSE Audit Committee Non-Compliance - TipRanks

Can Fite Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Can Stock often depends not only on the future outlook of the current and potential Can Fite's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Can Fite's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding362.7 K
Cash And Short Term Investments7.9 M

Can Fite Fundamentals Growth

Can Stock prices reflect investors' perceptions of the future prospects and financial health of Can Fite, and Can Fite fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Can Stock performance.

About Can Fite Performance

By analyzing Can Fite's fundamental ratios, stakeholders can gain valuable insights into Can Fite's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Can Fite has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Can Fite has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.78)(0.82)
Return On Capital Employed(1.32)(1.26)
Return On Assets(0.78)(0.82)
Return On Equity(1.67)(1.75)

Things to note about Can Fite Biopharma performance evaluation

Checking the ongoing alerts about Can Fite for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Can Fite Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Can Fite Biopharma generated a negative expected return over the last 90 days
Can Fite Biopharma has high historical volatility and very poor performance
The company reported the previous year's revenue of 674 K. Net Loss for the year was (7.88 M) with profit before overhead, payroll, taxes, and interest of 560 K.
Can Fite Biopharma currently holds about 12.77 M in cash with (7.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.
Can Fite Biopharma has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: Can-Fite BioPharma Calls March 3 Special Meeting to Address NYSE Audit Committee Non-Compliance - TipRanks
Evaluating Can Fite's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Can Fite's stock performance include:
  • Analyzing Can Fite's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Can Fite's stock is overvalued or undervalued compared to its peers.
  • Examining Can Fite's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Can Fite's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Can Fite's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Can Fite's stock. These opinions can provide insight into Can Fite's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Can Fite's stock performance is not an exact science, and many factors can impact Can Fite's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Can Stock analysis

When running Can Fite's price analysis, check to measure Can Fite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Can Fite is operating at the current time. Most of Can Fite's value examination focuses on studying past and present price action to predict the probability of Can Fite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Can Fite's price. Additionally, you may evaluate how the addition of Can Fite to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Fundamental Analysis
View fundamental data based on most recent published financial statements
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
CEOs Directory
Screen CEOs from public companies around the world
Commodity Directory
Find actively traded commodities issued by global exchanges